A Phase 3 interventional study of RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine) in Crohn Disease, sponsored by RedHill Biopharma Limited. Completed at 24 sites in 7 countries. Open to participants aged 18 Years to 76 Years. Per ClinicalTrials.gov, last updated 2021-02-24.
Sponsored by RedHill Biopharma Limited · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 161 studies in Crohn Disease with a site in Poland — 34 open to participants now, 51 under way, 32 of them phase 3. Crohn Disease · Poland.
Among the 161 studies in Crohn Disease with a site in Poland, this one is the 132nd largest by enrollment of the 152 interventional ones that give a count, is one of 10 that started in 2017, is one of 83 in phase 3, and was the 63rd registered.
1,993 studies on the registry are indexed under Crohn Disease; 478 are open to participants now.
Browse Crohn Disease studies →34 of the 161 studies in Crohn Disease with a site in Poland are open now. Recruiting first, the newest first:
Janssen Research & Development, LLC · Sites in Poland, United States, Argentina and 27 more countries
Ages 18+
Eli Lilly and Company · Sites in Poland, United States, Belgium and 7 more countries
Ages 18–80
Eli Lilly and Company · Sites in Poland, United States, Belgium and 7 more countries
Ages 18–80
Janssen Research & Development, LLC · Sites in Poland, United States, Austria and 14 more countries
Ages 18+
GLSMED Learning Health S.A. · Sites in Poland, Italy, Netherlands and 3 more countries
Ages 16–35 · Healthy volunteers
A study can be open while its sites in Poland have not opened yet or have stopped. Only those recruiting at a site in Poland →
Of the 353 Crohn Disease studies recruiting now, 154 (44%) set no upper age limit and 144 (41%) stop at 75 or younger; 95 take children under 18; 56 take healthy volunteers.
This study: 18 Years to 76 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
161 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 62 · Phase 3 89 · Phase 4 2
First in 2002; this study’s year is marked. 10 started in 2017.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 54 is below the median of 67 across 1,261 interventional studies indexed under Crohn Disease.
Median enrollment 192 across the 152 interventional studies, 400 across the 9 observational. Of the 106 that completed or were terminated, 83 (78%) have results posted.
This tab as a report to print or save as PDF → With an account.
150 of 161 have an industry lead sponsor. The 10 most frequent:
RedHill Biopharma Limited is the lead sponsor of 19 studies on the registry; 2 are open to participants now.
Of its 7 completed or terminated interventional studies of FDA-regulated products, 5 (71%) have results posted.
RedHill Biopharma Limited has 2 studies filed under Crohn Disease — fewer than ten, so there is no comparison to draw.
17 of the studies in Crohn Disease with a site in Poland that are under way reach primary completion within a year, 8 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06063967Phase 3AbbVieA Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease. | 2027-03 |
| NCT05347095Phase 3Janssen-Cilag Ltd.A Study of Guselkumab in Participants With Fistulizing, Perianal Crohn's Disease | 2027-03-25 |
| NCT06408935Phase 3Janssen-Cilag Ltd.Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients | 2027-06-08 |
| NCT06227910Phase 3TakedaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease | 2027-06-08 |
| NCT03345823Phase 3AbbVieA Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433 | 2027-09 |
Add all 17 to your calendar (.ics) → With an account.
Among the 161 studies in Crohn Disease with a site in Poland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An open label extension to the RHB-104-01 Study.
An Open Label Phase III Study to Assess the Efficacy and Safety of Fixed-Dose Combination RHB-104 in Subjects with Active Crohn's Disease Despite 26 Weeks of Participation in the MAP US RHB-104-01 Study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
OR
Current treatment with at least one of the following therapies which may be discontinued by the investigator as clinically indicated after 8 weeks of open label RHB-104 treatment:
Subject agrees to use the following effective methods
In regions where local regulatory contraceptive requirements differ, the ICF (Informed Consent Form) will reflect local policies.
Exclusion Criteria:
abnormalities of hematology or biochemistry as confirmed by repeat testing based on investigator's discretion, including but not limited to, elevations greater than 2 times the of (AST), Alanine Aminotransferase (ALT), Alkaline Phosphatase (ALP) or less than 60 ml/min at screening via estimated Cockcroft-Gault formula:
Creatinine Clearance = [140 - age in years] * weight (kg) / 72 * Serum Creatinine (mg/dl) [multiply estimated rate by 0.85 for women], using actual body weight.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects who were on the active therapy arm in the RHB-104-01 clinical study will continue to receive RHB-104 at 5 capsules twice a day in addition to the standard of care they received in the RHB-104-01 clinical study
Drug: RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)
Subjects who were on the active therapy arm in the RHB-104-01 clinical study will receive RHB-104 at 5 capsules twice a day in addition to the standard of care they received in the RHB-104-01 clinical study. The RHB-104 will be ramped up beginning at 1 capsule twice per day in week 1 increasing to 2 capsules twice per day in week 2, 3 capsules twice per day in week 3, 4 capsules per day in week 4 and achieving 5 capsules per day for the remainder of the study.
Drug: RHB-104 (fixed-dose combination: 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine)
Drug page: Clarithromycin
For patients on ACTIVE or PLACEBO in the parent study (RHB-104-01), who were not in remission after 26 weeks
Also known as: RHB-104
Number of Patients in Remission at Week 16
The number of patients who achieved a reduction of the total Crohn's Disease Activity Index (CDAI) score to less than 150 points. Lower CDAI scores indicate a better outcome.
Time frame: Week 16
Response at Week 16
Reduction of the total Crohn's Disease Activity Index (CDAI) score by a minimum of 100 points Lower CDAI scores indicate a better outcome.
Time frame: Week 16
The Number of Weeks for Patients to Achieve Remission
\[Date of first observed remission (CDAI less than 150) - date of first dose, or date of randomization if not dosed, plus 1\] / 7 days. Subject who never experience remission during the study are censored at the time of their last CDAI assessment.
Time frame: Baseline through week 52
Number of Weeks the Patients Are in Remission
Duration of remission is defined as the number of weeks the subject is in remission (CDAI score \< 150). It is calculated as the first date following remission at which CDAI is ≥150 minus the date of first remission, plus 1 day, divided by 7. Subjects who experienced remission and continued to be in remission at the time of their last CDAI assessment are censored at the date of their last CDAI assessment.
Time frame: Baseline through week 52
Number of Weeks to Achieve Response
\[Date of first observed response (a reduction from baseline of ≥ 100 in CDAI score) - Date of first dose or date of randomization if not dosed + 1\] / 7 Days. Subjects who never experienced response during the study are censored at the date of their last CDAI assessment.
Time frame: Baseline through week 52
Number of Weeks the Patients Are in Response.
Duration of response is defined as the number of weeks the subject is in a state of response (a reduction from baseline of ≥ 100 in CDAI score). It is calculated as the first date following response at which the reduction from baseline in CDAI is \<100 minus the date of first response, plus 1 day, divided by 7. Subjects who experienced response and continued to be in response at the time of their last CDAI assessment are censored at the date of their last CDAI assessment.
Time frame: Baseline through week 52
Durable Remission Week 16 Through Week 52
When a subject is in remission with a maximum CDAI score of 149 at every visit from week 16 through and including week 52.
Time frame: Week 16 through week 52
Increase in Milliseconds (ms) QT Wave
The increase in the number of milliseconds change-from-baseline to week 52 in QTcF (Fridericia's Correction Formula of QT wave interval) (based on cardiac safety report).
Time frame: week 52
| Milestone | RHB-104 From RHB-104 | RHB-104 From Placebo |
|---|---|---|
| Started | 16 | 38 |
| Completed | 9 | 21 |
| Not completed | 7 | 17 |
The number of patients who achieved a reduction of the total Crohn's Disease Activity Index (CDAI) score to less than 150 points. Lower CDAI scores indicate a better outcome.
| Participants | RHB-104 From ACTIVE Arm of RHB-104-01 | RHB-104 From PLACEBO Arm of RHB-104-01 |
|---|---|---|
| Number of Patients in Remission at Week 16 | 3 | 14 |
Reduction of the total Crohn's Disease Activity Index (CDAI) score by a minimum of 100 points Lower CDAI scores indicate a better outcome.
| Participants | RHB-104 From ACTIVE Arm of RHB-104-01 | RHB-104 From PLACEBO Arm of RHB-104-01 |
|---|---|---|
| Response at Week 16 | 4 | 14 |
\[Date of first observed remission (CDAI less than 150) - date of first dose, or date of randomization if not dosed, plus 1\] / 7 days. Subject who never experience remission during the study are censored at the time of their last CDAI assessment.
| weeks | RHB-104 From ACTIVE Arm of RHB-104-01 | RHB-104 From PLACEBO Arm of RHB-104-01 |
|---|---|---|
| The Number of Weeks for Patients to Achieve Remission | NA (NA to NA) | 25.1 (16.00 to 56.00) |
Duration of remission is defined as the number of weeks the subject is in remission (CDAI score \< 150). It is calculated as the first date following remission at which CDAI is ≥150 minus the date of first remission, plus 1 day, divided by 7. Subjects who experienced remission and continued to be in remission at the time of their last CDAI assessment are censored at the date of their last CDAI assessment.
| weeks | RHB-104 From ACTIVE Arm of RHB-104-01 | RHB-104 From PLACEBO Arm of RHB-104-01 |
|---|---|---|
| Number of Weeks the Patients Are in Remission | 11.7 (NA to NA) | 45.0 (23.00 to NA) |
\[Date of first observed response (a reduction from baseline of ≥ 100 in CDAI score) - Date of first dose or date of randomization if not dosed + 1\] / 7 Days. Subjects who never experienced response during the study are censored at the date of their last CDAI assessment.
| Weeks | RHB-104 From ACTIVE Arm of RHB-104-01 | RHB-104 From PLACEBO Arm of RHB-104-01 |
|---|---|---|
| Number of Weeks to Achieve Response | NA (16.14 to NA) | 26.1 (9.14 to 56.00) |
Duration of response is defined as the number of weeks the subject is in a state of response (a reduction from baseline of ≥ 100 in CDAI score). It is calculated as the first date following response at which the reduction from baseline in CDAI is \<100 minus the date of first response, plus 1 day, divided by 7. Subjects who experienced response and continued to be in response at the time of their last CDAI assessment are censored at the date of their last CDAI assessment.
| Weeks | RHB-104 From ACTIVE Arm of RHB-104-01 | RHB-104 From PLACEBO Arm of RHB-104-01 |
|---|---|---|
| Number of Weeks the Patients Are in Response. | 29.4 (10.86 to NA) | 45.0 (26.14 to NA) |
When a subject is in remission with a maximum CDAI score of 149 at every visit from week 16 through and including week 52.
| Participants | RHB-104 From ACTIVE Arm of RHB-104-01 | RHB-104 From PLACEBO Arm of RHB-104-01 |
|---|---|---|
| Durable Remission Week 16 Through Week 52 | 1 | 7 |
The increase in the number of milliseconds change-from-baseline to week 52 in QTcF (Fridericia's Correction Formula of QT wave interval) (based on cardiac safety report).
| ms | RHB-104 From ACTIVE Arm of RHB-104-01 | RHB-104 From PLACEBO Arm of RHB-104-01 |
|---|---|---|
| Increase in Milliseconds (ms) QT Wave | 23.9 (17.77 to 30.02) | 27.6 (23.66 to 31.63) |
Collected over Baseline through 30 days after last dose of study drug, or up to 13 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| RHB-104 From RHB-104 | 0/16 (0%) | 1/16 (6.3%) | 14/16 (87.5%) |
| RHB-104 From Placebo | 0/38 (0%) | 4/38 (10.5%) | 24/38 (63.2%) |
| Event | RHB-104 From RHB-104 | RHB-104 From Placebo |
|---|---|---|
| Crohn's diseaseGastrointestinal disorders | 1/16 | 0/38 |
| Abdominal PainGastrointestinal disorders | 0/16 | 1/38 |
| DiverticulitisInfections and infestations | 0/16 | 1/38 |
| Procedural painInjury, poisoning and procedural complications | 0/16 | 1/38 |
| Acute respiratory failureRespiratory, thoracic and mediastinal disorders | 0/16 | 1/38 |
| Peripheral Arterial Occlusive DiseaseVascular disorders | 0/16 | 1/38 |
| Event | RHB-104 From RHB-104 | RHB-104 From Placebo |
|---|---|---|
| ChromaturiaRenal and urinary disorders | 2/16 | 9/38 |
| Crohn's DiseaseGastrointestinal disorders | 1/16 | 6/38 |
| NauseaGastrointestinal disorders | 2/16 | 4/38 |
| Abdominal painGastrointestinal disorders | 2/16 | 3/38 |
| Dry mouthGastrointestinal disorders | 2/16 | 1/38 |
| Weight decreasedInvestigations | 2/16 | 1/38 |
| Weight increasedInvestigations | 2/16 | 1/38 |
| Urinary tract infectionInfections and infestations | 2/16 | 2/38 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 2/16 | 3/38 |
| VomitingGastrointestinal disorders | 1/16 | 3/38 |
Total Study
| Age, Continuous(years) | RHB-104 |
|---|---|
| RHB-104 from RHB-104 | 48.6 ± 9.92 |
| RHB-104 from placebo | 40.0 ± 13.24 |
| Sex: Female, Male(Participants) | RHB-104 |
|---|---|
| RHB-104 from RHB-104 — Female | 6 |
| RHB-104 from RHB-104 — Male | 10 |
| RHB-104 from placebo — Female | 18 |
| RHB-104 from placebo — Male | 20 |
| Race (NIH/OMB)(Participants) | RHB-104 |
|---|---|
| RHB-104 from RHB-104 — American Indian or Alaska Native | 0 |
| RHB-104 from RHB-104 — Asian | 0 |
| RHB-104 from RHB-104 — Native Hawaiian or Other Pacific Islander | 0 |
| RHB-104 from RHB-104 — Black or African American | 1 |
| RHB-104 from RHB-104 — White | 15 |
| RHB-104 from RHB-104 — More than one race | 0 |
| RHB-104 from RHB-104 — Unknown or Not Reported | 0 |
| RHB-104 from placebo — American Indian or Alaska Native | 1 |
| RHB-104 from placebo — Asian | 0 |
| RHB-104 from placebo — Native Hawaiian or Other Pacific Islander | 0 |
| RHB-104 from placebo — Black or African American | 1 |
| RHB-104 from placebo — White | 36 |
| RHB-104 from placebo — More than one race | 0 |
| RHB-104 from placebo — Unknown or Not Reported | 0 |
| Baseline Crohn's Disease Activity Index (CDAI) score(units on a scale) | RHB-104 |
|---|---|
| RHB-104 from RHB-104 | 295.42 ± 82.865 |
| RHB-104 from placebo | 271.67 ± 58.379 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Mar 2017 to primary completion in Nov 2018, 19 months.
Results were first posted in Feb 2021, 2 years 3 months after primary completion.
Of 70 industry-sponsored phase 3 interventional studies under Crohn Disease, half reached primary completion within 46 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 69. This study's 19 months is below that.
Counting every sponsor, half of 88 studies reached it within 49 months; a quarter within 36 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Clarithromycin
RedHill Biopharma Limited